Lyon - Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, announces the extension of the capacities of NeuroLead, its discovery platform drug candidates, autophagy and neurologically expressed lysosomal diseases.
NeuroLead, which combines the latest innovations in neuroscience and artificial intelligence, is a platform for generating new drug candidates from a unique concept, the therapeutic targeting of interactions between glial and neuronal cells. By applying Neurolead to autophagy and to the neurological forms of lysosomal diseases, Theranexus is continuing its research on a therapeutic axis of major interest, presenting strong medico-economic challenges.
The common point of lysosomal diseases is a genetic deficiency leading to a malfunction of lysosomes cellular organelles responsible for the degradation of numerous biomolecules. With the drug candidate BBDF-101 in Batten disease, Theranexus is already working on a juvenile form of lysosomal disease which is characterized by the accumulation of lipoproteins in the brain.
The NeuroLead platform has already made it possible to develop and validate various cellular models for studying autophagy, the biological process of recycling biomolecules by lysosomes. Theranexus has thus identified, by screening, various drug structures capable of acting, by various pathways, on cellular autophagy and lysosome function. This work is also reinforced by complementary in silico approaches, combining artificial intelligence and research in massive databases, and offering a better characterization of the classes of structures identified.
'The results of this research, based on the use of our models of interactions between neurons and astrocytes in a pathological context, open up new avenues for discovering drugs that modulate autophagy . This work will enable us to strengthen the industrial value potential of our platform to provide solutions adapted to the strong needs of the many patients with lysosomal diseases. ' Specifies Mathieu Charveriat, Scientific Director of Theranexus.
'There are 50 varieties of lysosomal diseases that affect more than 3,000 adults and children in France. 150 new cases are diagnosed each year. These diseases lead to the appearance of lesions in various organs: bones, heart, lungs, liver, spleen, brain, etc. causing particularly serious and irreversible disorders. Today, there are only 14 advanced treatments in France for 11 lysosomal diseases which is very insufficient given that these diseases very often lead to multiple disabilities and are life threatening. We have a real need for new treatments to overcome these diseases. 'Adds Stephane Antolin, president of the Association Vaincre les Maladies Lysosomales.
Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company from CEA that develops drug candidates for the treatment of diseases of the nervous system.
Thanks to its knowledge of neuro-glial interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of active ingredients in the clinical phase. This strategy of combining repositioned drugs based on a solid commercial case and having a real ability to quickly demonstrate their clinical value allows the company to generate different high value-added proprietary drug candidates, significantly reducing the time and costs of development and considerably increase the chances of market access for its drugs.
To this end, THERANEXUS is positioned in several indications, including Parkinson's disease and Batten disease, for which no treatment is currently available on the market.
Tel: +33 (0) 1 53 67 36 70